Abstract:
Methods for rescuing learning, memory and/or motor function deficits associated with frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U) are disclosed. The method comprises: a) administering to an animal having FTLD-U a therapeutically effective amount of an autophagy inducer; b) causing a decrease in the amount of ubiquitinated TDP-43 aggregation forms in the brain of the animal; and c) causing an improvement of the learning, memory capacities and/or motor function of the animal.
Abstract:
A nanosheet includes a 2H—SiC layer having a first surface and a second surface, the first and second surfaces being opposed to each other; a first graphene layer formed of 1-10 graphenes being disposed on the first surface; and a second graphene layer formed of 1-10 graphenes being disposed on the second surface.
Abstract:
A novel system and methods for accelerating analytes including, without limitation, molecular ions, biomolecules, polymers, nano- and microparticles, is provided. The invention can be useful for increasing detection sensitivity in applications such as mass spectrometry, performing collision-induced dissociation molecular structure analysis, and probing surfaces and samples using accelerated analyte.
Abstract:
A method for preparing luminescent diamond particles (e.g., fluorescent nanodiamonds). The method includes irradiating diamond particles with an ion beam and heating the irradiated diamond particles in a non-oxidizing atmosphere at a temperature between 600 and 1000° C. The diamond particles have a diameter of 1 nm to 1 mm and the ion beam has a kinetic energy of 1 KeV to 900 MeV. Also disclosed are luminescent diamond particles prepared by this method and methods of using them.
Abstract:
This invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601).
Abstract:
Disclosed are recombinant non-insect host cells and use of activation of CMV or SV40 promoters by IE1, IE2 and the enhancer hr of the baculovirus in non-insect host cells for expression heterologous RNAs or polypeptides. Also disclosed are methods of using the cells.
Abstract:
An approach to measuring power consumption of multiple appliances adopts a transition probability to model the correlation and causality of appliance events caused by human behavior. The sequential order and relevance of using appliances can be taken into account. For instance, correlation between the use of (e.g., states of) different electrical appliances may be used.
Abstract:
A transistor includes a first semiconductor layer associated with a first electrode; a second semiconductor layer associated with a second electrode; and a discontinuous layer between the first and second semiconductor layer. The discontinuous layer has a plurality of openings being formed on a non-uniform organic surface. Applications of the transistor include an inverter that operates at low supply voltage and high frequency.
Abstract:
A method of treating a Th1-mediated disorder includes administering to a subject in need of the treatment an effective amount of a compound of the formula I: wherein R1 is H, alkyl, aryl, or cyclyl; R2 is pyranose; R3 is H or alkyl; m is 2, 3, 4, 5, or 6; n is 0, 1, 2, or 3; o is 0, 1, 2, 3, 4; p is 1, 2, 3, or 4; and the Th1-mediated disorder is non-obese diabetes, Crohn's colitis, autoimmune hemolytic anemia, rheumatoid arthritis, autoimmune encephalitis, multiple sclerosis, or autoimmune myocarditis. Also disclosed is a pharmaceutical composition including a compound of formula I above and a pharmaceutically acceptable carrier.